How Josephs was paid
$545,635 in total for 2025T, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Incentive | Other | Total |
|---|---|---|---|---|
| Paul JosephsPresident and Chief Executive Officer | $331,154 | $198,692 | $15,789 | $545,635 |
| Ryan D. LakeExecutive Vice President, Chief Financial Officer | $277,662 | $99,958 | $29,069 | $406,689 |
| Thomas D. SalusChief Legal and Administrative Officer | $265,385 | $99,519 | $18,895 | $383,799 |
What changed and why
- $546KCEO Paul Josephs received total compensation of $545,635 for the 2025 transition period.
- 80%The Compensation Committee emphasized Company financial goals and weighted financial components at 80% of incentive pay.
- 98.7%Stockholders expressed strong support for the executive compensation program with 98.7% approval at the 2025 annual meeting.
- The transition period covered May 26, 2025 through December 31, 2025 due to a fiscal year change.
Other Lifecore Biomedical proxy statements
- 2025 proxy statement
Paul Josephs paid $1.1M (-89% on the year), pay ratio 15:1.
Filed Sep 18, 2025
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.